We welcome requests for further information or interviews.
Robert Robinson Avenue
The Oxford Science Park
Circassia is a world-class specialty pharmaceutical business focused on respiratory disease. Circassia sells its novel, market-leading NIOX® asthma management products directly to specialists in the United States, United Kingdom and Germany, and in a wide range of other countries through its network of partners. The Company recently established a collaboration with AstraZeneca in the US in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza®, and has the US commercial rights to the late-stage COPD product Duaklir®*.
Circassia’s development pipeline includes a range of respiratory medicines. The Company’s lead asthma treatment targets substitution of GSK’s Flixotide® pMDI and was approved in the UK. Circassia is also developing a direct substitute for Seretide® pMDI, and its pipeline includes a number of inhaled medicines for COPD, including single and combination dose products.
*The Duaklir® trademark is registered in the United States; the mark is not currently approved for use by the FDA.
Circassia Pharmaceuticals plc may use your personal information to contact you by email, telephone or post to respond to your query.